In this paper, we have demonstrated that isotype-switched antibodies targeting PLP181−230 are significantly elevated in the serum of patients with RR-MS and SP-MS, particularly in those carrying PLP response-permissive HLA types, and that there is a positive correlation between the levels of antibody and disease severity in these patients. The gene discussed is PLP1; the disease is myeloid sarcoma.